

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Benigno Rodriguez, MD	POSITION TITLE Assistant Professor of Medicine Associate Director, CWRU Center for AIDS Research Clinical Core		
eRA COMMONS USER NAME			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Javeriana University, Bogota, Colombia	MSc	Current	Clinical Epidemiology and Biostatistics
Gorgas Memorial Institute, University of Alabama and Peruvian University "Cayetano Heredia"	Diploma	1997	Clinical Tropical Med & Hygiene
University of Valencia, Spain	Master's	1996	Tropical & Parasitic Diseases
Javeriana University School of Med, Bogota, Colombia	MD	1990	Medicine

A. Positions and Honors.

2004-Present	Assistant Professor of Medicine, Case Western Reserve University Division of Infectious Diseases, Cleveland, OH
1997-2003	Assistant Professor, Internal Medicine and Infectious Diseases. Javeriana University School of Medicine, Bogota, Colombia.
2003-2004	Fellow, HIV Medicine. Case Western Reserve University/University Hospitals of Cleveland, Cleveland, OH.
2002-2003	Chief Fellow, Division of Infectious Diseases. Case Western Reserve University/University Hospitals of Cleveland, Cleveland, OH.
2000-2002	Fellow, Infectious Diseases. Case Western Reserve University/University Hospitals of Cleveland, Cleveland, OH.
1997-2000	Chairman, Committee for the Prevention and Control of Nosocomial Infections. San Ignacio University Hospital, Bogota, Colombia.
1995-1997	Instructor, Internal Medicine and Infectious Diseases. Javeriana University School of Medicine, Bogota, Colombia.
1995	Instructor of Internal Medicine, Emergency Dept. San Ignacio University Hospital, Bogota, Colombia.
1992-1995	Resident, Internal Medicine. San Ignacio University Hospital, Bogota, Colombia.
1990-1992	Director, El Pando Healthcare Center and staff physician, Intensive Care Unit, San Juan de Dios Hospital, Santa Marta, Colombia.

COMMITTEES, STUDY SECTIONS, ADVISORIES

2005	Reviewer, Universitywide AIDS Research Program for the Basic Clinical/HIV Treatment, Opportunistic Infections and HIV-Related Malignancies Study Section, University of California
2005	Reviewer, NIH AIDS Discovery and Development of Therapeutics Study Section
2003-2004	Experimental Therapeutics Research Agenda Committee, AIDS Clinical Trials Group.
1999-Present	Editorial Board, Travel Medicine Monthly
1999-Present	Scientific Advisor, Shoreland

B. Peer-reviewed publications

- Rodríguez B**, Sethi AK, Cheruvu V, Mackay W, Bosch RJ, Kitahata M, Boswell SL, Matthews C, Bangsberg D, Martin J, Whalen CC, Yadavalli S, Sieg S, Deeks S, Lederman MM. Presenting Plasma Viremia Is a Minor Determinant of CD4 T Cell Losses in Untreated HIV Infection. Lancet 2005. Submitted.
- Rodríguez B**, Valdez H, Mijch A, Watson K, Lederman MM, McComsey GA, Loupa CV, Woolley I. Statins Transiently Blunt HAART-Induced CD4+ T Cell Gains, But Have No Long-Term Effect On Virologic Response To HAART. AIDS 2005. In press.
- Loupa CV, Lederman MM, Valdez H, Salata RA, McComsey GA, Gripshover B, Fulton S, Lisgaris MV, Kucia M, Asaad R, Cline J, **Rodríguez B**. New Entrants to HIV Care Are Presenting Only at Marginally Earlier Stages of Disease but May Increasingly Represent Groups Perceived at Lower Risk. J Int Assoc Physicians AIDS Care 2005. In press.

Principal Investigator/Program Director (Last, First, Middle):

4. Sieg SF, Asaad R, Jiang W, Bazdar DA, Lederman MM. Peripheral S Phase T Cells in HIV Disease Have a Central Memory Phenotype and Largely Lack Evidence for Recent T Cell Receptor Engagement. J Infect Dis 2005. In press.
5. Jiang W, Lederman MM, Salkowitz JR, **Rodríguez B**, Harding CV, Sieg SF. Impaired Monocyte Maturation in Response to CpG Oligodeoxynucleotide is Related to Viral RNA Levels in HIV Disease and Is At Least Partially Mediated by Deficiencies in Type I Interferon Responsiveness and Production. J Virol 2005; 79: 109-19.
6. Lederman MM, Veazey RS, Mosier DE, Hartley O, Dufour J, Mefford M, Piatak M, Lifson JD, **Rodríguez B**, Blauvelt A, Offord RE. Targeted Inhibition of CCR5 with PSC-RANTES Is Sufficient to Block Intravaginal Transmission of SHIV in Rhesus Macaques. Science 2004; 306: 485-487.
7. Lederman MM, **Rodríguez B**, Sieg SF. Immunopathogenesis of HIV-1 Infection. In: Peipert L, Volberding PA, Eds. HIV InSite Knowledge Base. <http://hivinsite.ucsf.edu/InSite?page=KB-02-01-04>. 2004.
8. Chakraborty B, Kiser P, Rangel HR, Weber J, Mirza M, Marotta ML, Asaad R, **Rodríguez B**, Valdez H, Lederman MM, Quiñones-Mateu M. Can HIV-1 Superinfection Compromise Antiretroviral Therapy? AIDS 2004; 18: 132-134.
9. Perez A, Dennis RJ, **Rodríguez B**, Castro AY, Delgado V, Lozano JM, Castro MC. An Interrupted Time Series Analysis of Parental Antibiotic Use in Colombia. J Clin Epidemiol, 2003; 56: 1013-20.
10. **Rodríguez B**, Valdez H, Friemuth W, Butler T, Asaad R, Lederman MM. Plasma Levels of B-lymphocyte Stimulator (BLyS) Increase with HIV Disease Progression. AIDS, 17:1983-1985, 2003.
11. Hunt PW, Deeks SG, **Rodríguez B**, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TP, Brand RJ, Lederman MM, Martin JN. Continued CD4+ T-cell Count Increases in HIV-infected Adults Experiencing Four Years of Viral Suppression on Highly Active Antiretroviral Therapy. AIDS, 17:1907-1915, 2003.
12. Roy S, Schreiber JR, John CC, Kaplan EL, **Rodríguez B**, Salata RA, Palavecino E. A Family Cluster of Five Cases of Group A Streptococcal Pneumonia. Pediatrics 112: e61 – e65, 2003.
13. **Rodríguez B**, Woolley I, Lederman MM, Zdunek D, Hess G, Valdez H. Effect of GB Virus C Coinfection on Response to Antiretroviral Treatment in Human Immunodeficiency Virus-Infected Patients. J Infect Dis 187: 504-507, 2003.
14. **Rodríguez B**, Vásquez, O. Sussmann, S. Máttar, C. A. Jaramillo. Antimicrobial Susceptibility and Serotyping of *Pseudomonas aeruginosa* Strains Isolated in Bogota, Colombia. Eur J Clin Microbiol Infect Dis 19: 152 – 154, 2000.
15. **Rodríguez B**. Diagnóstico Diferencial de la Diarrea en Pacientes con SIDA. Acta Biomedica Colombiana 2: 22 – 28, 1994.
16. **Rodríguez B**. Estado Actual del Uso de los Aminoglicósidos en Neumonía por Gram-negativos. Universitas Medica 35: 44 – 47, 1994.
17. **Rodríguez B**. Osteoporosis en el Anciano. Tribuna Medica Colombiana 92: 275 – 281, 1995.
18. **Rodríguez B**. Farmacoterapia en el Anciano. Tribuna Medica Colombiana 92: 204 – 209, 1995.
19. **Rodríguez B**, Morillo LE, Sanín LC. Espectro Clínico de la Apnea Obstructiva del Sueño. Universitas Medica 35: 67 – 77, 1994.

C. Current Research Support

ONGOING

AI-25879 (Lederman)

1/1/00 – 12/31/04

NIH/NIAID

Adult AIDS Clinical Trials Unit

Develop, implement, and analyze results of clinical treatment trials for HIV infection and its complications

Role: Co-Investigator

AI-36219 (Lederman)

4/1/93-3/31/09

NIH/NIAID

Center for AIDS Research (CFAR)

Promote increased collaboration between basic and clinical researchers through a central administrative structure, development of appropriate forums for sharing and exchange of ideas and pilot funding for interdisciplinary research. Also to enhance the depth and breadth of AIDS research by coordinated development of core activities and recruitment of new investigators.

Role: Associate Director, Clinical Core; Coordinator of US-based studies, Clinical Epidemiology and Biostatistics Core

Principal Investigator/Program Director (Last, First, Middle):

AI-55793 (Landay) 7/15/03-12/31/06
NIH/NIAID

Basic and Clinical Studies of CpG ODN in HIV Disease

The overall goals of the projects are to determine: 1. how CpG ODN modify host adaptive and innate and adaptive immune responses in vitro; 2. how CpG ODN can be used as an adjuvant to enhance SIV-specific immune responses in a rhesus macaque model; and 3. examine the utility of CpG ODN to serve as a vaccine adjuvant in HIV-1 infected and uninfected persons.

Role: Co-Investigator

PENDING

PAR-01-056 (Anthony) *10/1/03 – 9/30/05 NIH

Interferon induction therapy of HCV in HCV-HIV coinfection

To determine whether high dose induction interferon-alpha followed by standard combination therapy with pegylated interferon-alpha plus ribavirin for HCV in HCV-1-HIV-1 coinfecting individuals leads to a more rapid and pronounced first phase viral decline, as well as a more rapid 2nd phase viral decline. Additionally, to establish whether the magnitude of HCV-specific IFN- γ producing T cell frequency and proliferation capacity is related to first and second phase viral decline.

Role: Co- Principal Investigator

Veterans Administration (Anthony) *10/1/04 – 9/30/05

Role of pDC1 pDC2 cells in host defense against HCV

To investigate the function of dendritic cell populations as they relate to T cell priming, the presence of memory effector T cell populations and viral response to therapy in HCV infection, with an ultimate goal of elucidating protective immunity in the HCV infected host.

Role: Co- Investigator

Interferon alpha and CD8 T cell activation in HIV (Sieg) 12/02/04 – 11/30/06
5%

To investigate the importance of and functional consequences of interferon-alpha-induced changes among CD8+T cell subsets. Results will contribute to our understanding of normal and abnormal immune regulation and the role of interferon-alpha in cross talk between branches of innate and adaptive immunity.

Role: Co-investigator

OVERLAP:

None

*Resubmission in preparation.